-
COVID-19 Case Analysis 23 Jan to 29 March 2020
- posted by: Lee Smith
- posted on: March 30, 2020
Animated bubble plot of cumulative COVID-19 cases & deaths by country.
Read the rest of this post -
Live Attenuated Viral Vaccines Advancements
- posted by: Lee Smith
- posted on: January 19, 2020
Innovation is continually taking place for a generation of new vaccines to meet patient needs across the globe. We focus here on two live attenuated viral vaccines that have quite different profiles; the first, dengue, a disease where no vaccine exists and the second, influenza, a disease for which there have been a number of vaccines available over the decades yet none that are universal.
Read the rest of this post -
Hope for Chlamydia STI Vaccine After Promising Initial Results
- posted by: Lee Smith
- posted on: November 4, 2019
A vaccine to protect against Chlamydia has taken a step closer to licensure after successful phase 1 clinical trials. The clinical studies were performed at Imperial College London and demonstrated the safety of the vaccine.
Read the rest of this post -
FluGen’s M2SR Influenza Vaccine Succeeds in Phase 2 Human Challenge Trial
- posted by: Lee Smith
- posted on: February 13, 2019
FluGen’s Influenza Vaccine Succeeds in Phase 2 Human Challenge Trial
Read the rest of this post -
Takeda Vaccine's Dengue Vaccine meets Primary Endpoints in its Phase III Efficacy Trial
- posted by: Lee Smith
- posted on: January 30, 2019
Takeda Vaccine's Dengue Vaccine meets its Primary Endpoints in Phase III Efficacy Trial.
Read the rest of this post -
Thoughts from the World Vaccine Congress, Washington 2018
- posted by: Lee Smith
- posted on: April 3, 2018
I'm currently attending the World Vaccine Congress 2018 in Washington to hear the latest musing from the sector's thought leaders and also find out about the latest technologies that are being used in the production of vaccines globally.
Read the rest of this post -
Chikungunya Vaccine UK Government Funding Secured By Themis Bioscience
- posted by: Lee Smith
- posted on: September 12, 2017
One year ago in September 2016 the UK's government innovation agency Innovate UK provided £1 million to help accelerate Themis' Zika candidate into the clinic. Now, a year on they are providing another £3 million for clinical trials to help propel the firm's Chikungunya vaccine forward.
Read the rest of this post -
GRA Client, Themis Bioscience Start Phase II Chikungunya Clinical Study In Endemic Area
- posted by: Lee Smith
- posted on: August 8, 2017
Themis Bioscience begins testing of their Chikungunya vaccine in Puerto Rico phase II clinical study
Read the rest of this post -
New Article: Public-Private Coalition's: High-Profile Delinkage Policy For Emerging Vaccines
- posted by: Lee Smith
- posted on: July 11, 2017
Recently I've contributed a small part in Tatum Anderson's April 2017 article Public-Private Coalition's: High-Profile Delinkage Policy For Emerging Vaccines.
Read the rest of this post